Molefy Pharma was founded in 2024 with the vision of transforming the future of healthcare. Born from the collaboration between CSIC and ARQUIMEA, we are driven by an unprecedented commitment to research and innovation. Our mission is clear: to revolutionize the treatment of neurodegenerative diseases with breakthrough therapies that challenge the status quo and offer new hope to patients.
The Spanish National Research Council (CSIC) is Spain’s leading public research institution and one of the most renowned in Europe. Dedicated to advancing scientific knowledge and technological innovation, CSIC plays a key role in bridging the gap between fundamental research and real-world applications through successful technology transfer initiatives.
ARQUIMEA is a Spanish technology company operating globally, providing innovative solutions and products in highly demanding sectors such as Aerospace, Defense & Security, Science Industry, and Fintech. With a strong commitment to research and development, ARQUIMEA fosters cutting-edge innovation through strategic collaborations.
Developed through a successful technology transfer between ARQUIMEA, the Spanish National Research Council (CSIC), and leading scientists, Molefy Pharma is bringing cutting-edge research closer to patients.
By combining scientific excellence with an agile, industry-driven approach, Molefy Pharma is working to bring new alternatives to ALS patients through innovative drug development.
At Molefy Pharma, we bring together a unique combination of scientific excellence and business expertise. Our team is composed of highly specialized professionals with a strong track record in the pharmaceutical and R&D sectors, united by a shared commitment: to push the boundaries of biomedical and pharmaceutical research.
Together, we contribute innovation, determination, and vision to advance our mission of transforming the future of healthcare.
Alfonso de Egaña has extensive experience in management and business development within the pharmaceutical and biotechnology sectors. He served as CFO at CIC bioGUNE and was involved in the creation of Atlas Molecular Pharma. He is currently the CEO of Molefy Pharma.
Expert in drug discovery and medicinal chemistry, with over 25 years of experience in neurodegenerative diseases. She is a Research Professor at CIB-CSIC and co-founder of Molefy Pharma.
Scientist at CIB-CSIC specializing in therapies for neurodegenerative diseases. Her work focuses on translational research, and she is a co-founder of Molefy Pharma.
Dr. Tania Ortuño is a neuroscientist specialized in translating research into clinical applications. She has led projects in neuroscience and biotechnology and currently serves as Head of Operations at Molefy Pharma.
Dr. Sara Vidal is an expert in molecular biology and scientific team management. She leads the Biotechnology Department at ARQUIMEA Research Center and is an affiliate scientist at Molefy Pharma.
Dr. Mercedes Ruiz Estévez is a molecular biologist with experience in translational research. She leads the cell culture group at ARQUIMEA Research Center and supports the development of Molefy Pharma.
Dr. Jesús Delgado is an organic chemist and R&D expert with an international track record. He is currently Business Development Director at ARQUIMEA Research Center and supports Molefy Pharma’s expansion in the United States.
The Scientific Advisory Committee (SAC) provides independent, high-level scientific guidance in key areas for the advancement of Molefy Pharma. Its responsibilities include the evaluation of discovery programs, encompassing the assessment of scientific rationale, data robustness, and the interpretation of results derived from screening and compound identification activities.
In addition, the ASC contributes to the company’s strategic scientific positioning, ensuring that research programs remain aligned with the state of the art and the evolving competitive landscape of the sector. It also advises on external collaborations, academic interactions, and potential scientific partnerships relevant to the company’s objectives.
Expert in drug discovery and medicinal chemistry, with over 25 years of experience in neurodegenerative diseases. She is a Research Professor at CIB-CSIC and co-founder of Molefy Pharma.
Scientist at CIB-CSIC specializing in therapies for neurodegenerative diseases. Her work focuses on translational research, and she is a co-founder of Molefy Pharma.
Internationally recognized neurobiologist and professor at the University of California, San Diego, and member of the U.S. National Academy of Sciences. His research has been key to advancing the understanding of neurodegenerative diseases such as ALS and to the development of new therapeutic approaches.
To develop breakthrough therapies for neurodegenerative diseases, halting progression and restoring health, driven by innovation and a commitment to patients.
To create a world where neurodegenerative diseases are no longer a threat, bringing transformative solutions that restore hope to patients worldwide